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Summary
Human CD38 is a multifunctional protein involved in
diverse functions. As an enzyme, it is responsible for
the synthesis of two Ca2+ messengers, cADPR and
NAADP; as an antigen, it is involved in regulating cell
adhesion, differentiation, and proliferation. Besides,
CD38 is a marker of progression of HIV-1 infection
and a negative prognostic marker of B-CLL. We have
determined the crystal structure of the soluble extra-
cellular domain of human CD38 to 1.9 Å resolution.
The enzyme’s overall topology is similar to the related
proteins CD157 and the Aplysia ADP-ribosyl cyclase,
except with large structural changes at the two ter-
mini. The extended positively charged N terminus has
lateral associations with the other CD38 molecule in
the crystallographic asymmetric unit. The analysis of
the CD38 substrate binding models revealed two key
residues that may be critical in controlling CD38’s
multifunctionality of NAD hydrolysis, ADP-ribosyl cy-
clase, and cADPR hydrolysis activities.
Introduction
Human CD38 is a type II transmembrane glycoprotein
expressed by premature hematopoietic cells, lost by
mature cells and reexpressed on activated lympho-
cytes such as T cells, B cells, dendritic cells, and natu-
ral killer cells. As a transmembrane protein, full-length
human CD38 has 300 amino acid residues pertaining
to three domains: a short intracellular domain, a single
transmembrane helix domain, and a large extracellular
domain. The extracellular domain is an ectoenzyme (EC
3.2.2.5) that can synthesize cyclic ADP-ribose (cADPR)
and nicotinic acid adenine dinucleotide phosphate
(NAADP) from its substrates NAD and NADP, respec-
tively (Howard et al., 1993; Aarhus et al., 1995). Cyclic
ADP-ribose and NAADP (Lee and Aarhus, 1995; Lee et
al., 1989) are two second messengers that can mobilize
Ca2+ from intracellular stores and regulate Ca2+ signal-
ing (Guse et al., 1999; Lee, 2001; Partida-Sanchez et
al., 2001).
CD38 is expressed on the surface of activated lym-*Correspondence: qh22@cornell.edu (Q.H.); leehc@tc.umn.edu
(H.C.L.)
4 These authors contributed equally to this work.phocytes, and it is not a marker of disease diagnosis.
But, for patients with B cell chronic lymphocytic leuke-
mia (B-CLL), those that were CD38 positive showed a
shorter survival compared with those that were CD38
negative (Durig et al., 2002; Thornton et al., 2004; Ghia
et al., 2004). In human immunodeficiency virus type 1
(HIV-1)-infected patients, CD38 is a prognostic marker
of HIV-1 progression. The increase of CD38 expression
is an indicator of the disease progression, and the
decrease of CD38 expression is a good indicator of
the effectiveness of highly active antiretroviral therapy
(HAART) (Roussanov et al., 2000; Autran et al., 1997;
Vigano et al., 1998). It is intriguing that although CD38
is a diagnostic marker of HIV-1 progression, at the early
stage of HIV-1 infection, CD38 can actually prevent the
lymphocytes from HIV-1 infection in vitro (Savarino et
al., 1999). The molecular relationship between CD38
and HIV-1 was first identified by the interactions be-
tween CD38 and CD4, the main HIV-1 receptor (Dian-
zani et al., 1995). Further investigation showed that
CD38’s inhibition of HIV-1 infection is due to the molec-
ular interactions between the membrane-proximal por-
tion of the CD38 extracellular domain, CD4, and HIV-1
gp120 (Savarino et al., 2003). Recently, CD38 has also
been identified as playing a role in the regulation of the
migration of dendritic cells in the development of hu-
moral immunity (Partida-Sanchez et al., 2004).
As a cell surface receptor, CD38 has been found to
regulate lymphocyte adhesion to endothelial cells by
interplaying with its counterreceptor, CD31, an Ig su-
perfamily member involved in the HEC/lymphocyte ad-
hesion process (Deaglio et al., 1996, 1998). Further-
more, upon mAb ligation, CD38 can trigger signaling
pathways through lateral associations with other cell
surface molecules such as the TCR/CD3 complex in T
lymphocytes (Reinis et al., 1997; Morra et al., 1998), the
BCR complex in B lymphocytes (Lund et al., 1996;
Deaglio et al., 2003), and CD16 in NK cells (Deaglio et
al., 2002).
Here, we report the first, to our knowledge, crystallo-
graphic structure of the recombinant extracellular do-
main of human CD38 (shCD38) at 1.9 Å resolution. The
high-resolution structure of CD38 described in this
study should help in understanding the functions of this
protein, as well as provide structural clues for designing
potent drugs for the treatment of CD38-related dis-
eases such as AIDS, B-CLL, and diabetes.
Results and Discussion
Overall Structure
The final refined structural model contains two shCD38
molecules in the crystallographic asymmetric unit, each
consisting of 252 residues. The N-terminal secretion
sequence (KREAEAR) from the expression vector and
the C-terminal tail (TSEI) are disordered in both mole-
cules. The overall structure of the shCD38 molecule is
an “L”-shaped molecule and can be divided into two
separate domains. The N-terminal domain (residues
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133245–118 and 144–200) is formed by a bundle of α helices
(α1, α2, α3, α5, α6) and two short β strands (β1, β3);
and the C-terminal domain (residues 119–143 and 201–
300) consists of a four-stranded parallel β sheet (β2, β4,
β5, and β6) surrounded by two long helices (α8 and α9)
and two short helices (α4 and α7) (Figure 1A). Two
distinct domains are connected by a hinge region com-
posed of three peptide chains, including residues 118–
119, 143–144, and 200–201. A disulphide bond (Cys119-
Cys201), which is unique in CD38, in addition to the
other five pairs of disulphide bonds (Cys67-Cys82,
Cys99-Cys180, Cys160-Cys173, Cys254-Cys275, and
Cys287-Cys296) conserved in ADP-ribosyl cyclase family
members, further stabilizes the relative conformations
of two domains by linking peptides 118–119 and 200–
201 together. The formation of the disulphide bond by
residues Cys119 and Cys201 confirms the previous
prediction (Prasad et al., 1996).
Although the crystal structures of Aplysia cyclase
(Prasad et al., 1996; Love et al., 2004) and CD157 (Ya-
mamoto-Katayama et al., 2002) reveal head-to-head
and tail-to-tail homodimers, the two shCD38 molecules
do not form a dimer in the crystal. The two molecules
can be superimposed quite well, except for at the
N-terminal region (Figure 1B), where the N terminus in-
volved in lateral associations was observed to bend
further toward its own C terminus.
If shCD38 were aligned against the dimeric structure
of CD157 or the Aplysia cyclase (head-to-head and tail-
to-tail), there would be substantial structural clashes
between the two shCD38 molecules at the C-terminal
regions. Therefore, dimerization of shCD38 in the same
fashion as that observed in CD157 and Aplysia cyclase
would require significant structural rearrangement of
the C-terminal region of shCD38. This suggests that
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pFigure 1. The Overall Structure of shCD38
(A) Two views of a ribbon representation of the structure of shCD38 related by 90° rotation around a vertical axis. The peptide GPGTTK
involved in the inhibition of HIV-1 infection is colored in blue.
(B) Superimposition of the two shCD38 molecules. The N-terminal structures (in red) in two molecules are different due to the intermolecular in-
teractions.
All figures were prepared with Molscript (Kraulis, 1991), Pymol (http://pymol.sourceforge.net), or Swiss-Pdb Viewer (Guex and Peitsch, 1997)
and were rendered by PovRay (http://www.povray.org).oluble CD38 may not naturally form a dimer, or at least
ot in the same manner as that observed for CD157
nd the Aplysia cyclase. Indeed, there is evidence that
uggests that the structure of the enzymatic functional
hCD38 in solution may be a monomer (Funaro et al.,
996; Bruzzone et al., 1998).
On the other hand, there are reports that the full-
ength CD38 can form dimers on the cell surface (Bruz-
one et al., 1998; Moreno-Garcia et al., 2004), which
ppears to require structural contributions from the in-
racellular tail (Moreno-Garcia et al., 2004). Therefore,
n the absence of the transmembrane domain and the
ntracellular tail, shCD38 might not form a functional di-
er in solution or in crystals. The lateral intermolecular
ssociations observed in the crystal might be artifacts
ormed by the crystallographic packing force or by mo-
ecular aggregation.
The possibility that deglycosylation of shCD38 may
lter its dimerization was considered. The silencing of
he four glycosylation sites was essential for the suc-
ess of crystallization. However, the mutation of these
ites should not affect the dimerization of shCD38,
ince structural alignments of CD38 with CD157 and
he Aplysia cyclase reveal that the glycosylation sites
n both CD38 and CD157 do not take part in the for-
ation of dimers (results not shown). This is further
upported by the fact that, without glycosylation, the
plysia cyclase can still form functional dimers (Prasad
t al., 1996) and that deglycosylation of CD157 does
ot affect its dimerization (Yamamoto-Katayama et al.,
002).
equence Evolution Induces Structural Changes
he structure of shCD38 was solved by molecular re-
lacement by using a modified CD157 structure as the
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1333search model, even though the two proteins share low
sequence identities (w30%) (Figures 2A and 3A). The
structural alignment of shCD38 with CD157 and Aplysia
cyclase reveals that the shCD38 structure is similar
overall to the two related proteins, but that CD157 and
Aplysia cyclase overlap better with each other than
they do with shCD38. In fact, significant structural dif-
ferences were observed between shCD38 and its re-
lated proteins at the regions of the N terminus, the C
terminus, and at the flexible loops of 74–78, 137–141,
161–168, and 244–253 (Figure 2B). Due to the presence
of four residues (48QTWS51) at the N-terminal region,
the N-terminal shCD38 structure is longer than the
other two molecules. The extended N terminus resi-
dues (RWRQTW) have positively charged long side
chains (Figures 3B and 4B) and reside at the mem-
brane-proximal region, consistent with their abilities to
interact with the hydrophilic head of lipid rafts (Zubiaur
et al., 2002). At the C-terminal region, unexpected
structural changes were found between C-terminal he-Figure 2. Sequence and Structural Comparisons between shCD38 and Related Proteins
(A) Sequence alignment between shCD38, CD157/BST-1, and Aplysia cyclase.
(B) Structural comparison of ADP ribosyl cyclase family members (shCD38, green; CD157/BST-1, yellow; Aplysia cyclase, chocolate). These
areas of largest structural differences are marked by circled areas, and shCD38 was colored blue in these circled areas.
(C) Structural evolution at the C terminus. The color scheme is the same as in (B). Side chains where structural divergences occur are drawn
in ball-and-stick representation.lix α9 in shCD38 and the corresponding helix in CD157
(or Aplysia cyclase) (Figures 2B and 2C). In CD157 (or
Aplysia cyclase), helix α9 and β6 are parallel; however,
in shCD38, helix α9 makes anw90° turn to the left and
is roughly perpendicular to β6 (Figure 2C). A close in-
spection reveals that helix α9 in shCD38 shifts away
from the main chain direction of CD157 (or Aplysia cy-
clase) and follows the side chain direction of Asp230 in
CD157 (or Asn230 in Aplysia cyclase). Similarly, the
main chain of CD157 follows the side chain direction of
Ile278 in shCD38 (Figure 2C).
Previous analyses have shown that the exon-intron
structures of the three genes encoding the three related
proteins are remarkably similar, suggesting that they all
evolved from a common ancestral gene (Ferrero and
Malavasi, 2002; Nata et al., 1997). As the secondary
structural elements (strand-turn-helix) are the same at
region of 273–289 in all three molecules and their genes
were evolved from the same ancestor, it appears that
the CD38 gene endured a heavier evolutionary stress
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1334Figure 3. Surface Features
(A) Conservation of shCD38 compared with
CD157 and Aplysia cyclase. Two views are
related by 180°. Identical residues, con-
served residues, and different residues in
three proteins are marked in red, pink, and
yellow, respectively. The active site shows
the greatest residue conservation as com-
pared to other places.
(B) Electrostatic potential distribution mapped
on the surface (negative, red; neutral, white;
positive, blue). The N terminus is positively
charged and has the potential to interact
with the plasma lipids. The C terminus is
negatively charged and is essential for the
enzyme’s catalytic activity.important residues all reside in the central part of the
Figure 4. Self-Association Inducing Confor-
mational Changes
(A) The lateral associations of two shCD38
molecules (molecule B, ribbon representation;
molecule A, surface representation colored in
pink). Residues of molecule B involved in the
hydrophobic and polar interactions are drawn
in ball-and-stick representation colored in
blue (peptide 52GPGTTK57), marine (peptide
170YQ171), and red (N-terminal residues 46,
48, 50, and 51). The superimposed N-terminal
residues in molecule A are also drawn in gray
to demonstrate the conformational changes
induced by intermolecular association.
(B) Proposed orientation of shCD38 on the
cell surface and interactions between CD38
and lipid rafts. Red ellipses represent the polar groups of glycerophospholipids, sphingolipids, and cholesterol. The extracellular domain
(shCD38) is shown in surface representation mapped with electrostatics (negative, red; neutral, white; positive, blue). The transmembrane
helix (pink) is proposed as an extension of the N terminus of shCD38.
ciate with the membrane and other proteins. In thethan the BST1 and Aplysia ADRC genes. It is interesting
that the structural evolution occurs right after the con-
served residue Cys275. So, it can be inferred that struc-
tural changes occurring before Cys275 may be evolu-
tionarily disadvantaged and may not be able to
withstand natural selection. This would be the case if
the enzymatic activities of the protein are its crucial
functions. As will be discussed below, the catalytically
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hree proteins.
elf-Association and Site for the Inhibition
f HIV-1 Infection
lthough the two molecules observed in the crystal
ay not reflect the structure of native CD38 in mem-
ranes, they do offer insights into how CD38 may asso-
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1335crystal structure of shCD38, the intermolecular associa-
tions involve the residues in the N terminus of one
molecule and the C-terminal domain of the other (Fig-
ure 4A). The interacting residues in molecule B are
mainly located in the N terminus (residues 2–13); in-
teracting residues in molecule A are concentrated in
the C-terminal domain. The interaction of the two mole-
cules induces structural changes for the four N-ter-
minal residues in molecule B (45RWRQ48), as revealed
by structural comparison of the two molecules (Figures
1B and 4A). The conformational changes for the four
N-terminal residues in molecule B are not random, as
the electron density for N-terminal residues in both
molecules is good and there are no obvious intermolec-
ular interactions for the four N-terminal residues in
molecule A.
The association-induced conformational changes sug-
gest the possibility that the association of CD38 with
other cell surface molecules may also trigger the con-
formational changes in this region. Considering that the
full-length CD38 is a transmembrane protein with only
a single helix anchored on the plasma membrane, the
overall effect of conformational changes triggered by
intermolecular interactions is the movement of the en-
tire extracellular domain through the conformational
changes at the membrane-proximal region. As full-
length CD38s have been reported to also have associa-
tions with membrane lipid rafts (Zubiaur et al., 2002), it
is reasonable to assign such associations to the polar
interactions between positively charged extracellular
membrane proximity regions and negatively charged
polar groups of sphingolipids. A possible orientation of
shCD38 on the cell surface is schematically shown in
Figure 4B. We cannot rule out the possibilities that
sphingolipids can also bind to other sites of shCD38
because sphingolipids can inhibit CD38 enzyme activ-
ity presumably by interfering with the active site of the
molecule. (Hara-Yokoyama et al., 1996, 2001).
CD38 has been shown to interfere with interactions
between HIV-1 glycoprotein gp120 and HIV-1’s primary
receptor CD4 at the early stage of HIV-1 infection (Sav-
arino et al., 1999). Peptide 52GPGTTK57 in shCD38 has
been proposed to be the functional unit for the inhibi-
tion of HIV-1 and CD4 interaction (Savarino et al., 2003).
It is intriguing that this positively charged hexameric
peptide is located at the N-terminal membrane-proxi-
mal region and is involved in association with its homo-
partner (shown in Figure 4A). The structure of the short
peptide is stable as it forms an antiparallel β strand (β1)
structure with hydrogen bond interactions to β3 (Figure
1A). Although there might be some sequence homology
between the peptide and the tip of the HIV-1 gp120 V3
loop (Savarino et al., 2003), further examination of the
structure of the GPGTTK peptide shows that the GPG
in CD38 is part of a strand; this orientation is very dif-
ferent from the tight turn observed in the HIV antibody-
V3 peptide structures (Stanfield et al., 2004). Thus, the
CD38 structural data reveal that the GPG region of
CD38 does not resemble the HIV-1 gp120 V3 region.
During the lateral association with CD4 and/or the
HIV-1 envelope glycoprotein gp120, the extracellular
domain of CD38 may move due to the conformational
changes of four flexible residues (45RWRQ48) at the
membrane-proximal region. This movement is similarto the phenomena observed at the N-terminal region in
the crystal structure of shCD38, but does not involve
the hexameric peptide (52GPGTTK57).
One Active Site Realizes Multiple Functions
As an ectoenzyme, CD38 can catalyze the formation of
cADPR and ADPR from NAD, can hydrolyze cADPR to
ADPR, and can catalyze the base-exchange reaction
from NADP to NAADP both in solution and on the cell
surface (Aarhus et al., 1995; Howard et al., 1993). Cyclic
ADPR and NAADP are two second messengers that
can mobilize intracellular calcium stores and regulate
calcium signaling (Lee et al., 1989; Lee and Aarhus,
1995; Lee, 2001). It has been identified that all of these
functions mentioned above are realized by a unique
active site (Graeff et al., 2001; Munshi et al., 2000).
Therefore, the structural features of the active site may
provide insight into the enzyme’s multifunctionality. In
the crystal structure, CD38’s active site is located be-
tween two distinct domains and is constructed by heli-
ces α5 and α6 from the N-terminal domain and helix α7
and strand β5 from the C-terminal domain. The posi-
tions of residues Glu226, Trp125, and Trp189, which are
essential for the enzyme’s catalytic activity (Munshi et
al., 2000), are highly conserved and are essentially fixed
on these secondary structural elements (Figures 5A
and 5C). All of these residues are conserved across the
ADP-ribosyl cyclase family and have very similar con-
formation (shown in Figures 5B and 5D) and thus repre-
sent a structural feature characteristic of the family.
Trp125 and Trp189 are suggested as the residues for
recognizing and positioning the substrate by hydropho-
bic interactions (Munshi et al., 2000). Glu226 is the ca-
talytic residue that takes part in the formation of the
catalytic intermediate (Sauve et al., 2000), and mutation
of Glu226 to any other residue completely destroys all
of its catalytic activities (Munshi et al., 2000).
Polar Interaction Is Essential for the Hydrolysis
of cADPR
Although CD38, CD157, and Aplysia cyclase are all en-
zymes, there are differences in their catalytic proper-
ties. For example, CD38 and CD157 can produce and
hydrolyze cADPR, but Aplysia cyclase can only pro-
duce, but cannot hydrolyze, cADPR (reviewed in Lee,
2000). To evaluate the structural basis for the catalytic
differences, the active site structures of CD38, CD157,
and Aplysia cyclase were aligned. Two substrates of
CD38, cADPR and NMN, were fitted into the catalytic
site based on the structures of the NMN and substrate
analog Etheno-NADP in CD157 (PDB ID: 1ISJ and
1ISH). In the CD38-cADPR model, most interactions
between cADPR and CD38 are hydrophobic, except
for the hydrogen bond interactions involving Lys129,
Glu226, Glu146, and cADPR. Residue Glu226 is 3.0 Å
to one hydroxyl group of the ribose ring, but 5.0 Å to
the scissile adenine-glycosidic bond of cADPR (Figure
5B), too far to perform a direct nucleophilic attack. As
the single mutation of Lys129 to other neutral or nega-
tively charged residues completely eliminates CD38’s
cADPR hydrolase activity (Tohgo et al., 1997), Lys129 is
also essential for cADPR hydrolysis. The existence of
the hydrogen bond between Lys129 and cADPR shows
Structure
1336Figure 5. Catalytic Pocket and Binding Models of CD38-cADPR and CD38-NMN
(A) Active site structure. Residues involved in the active site (Glu226, Trp125, Trp189, and Glu146) are shown with electron density superim-
posed.
(B) Stereoview of a ball-and-stick representation of the CD38-cADPR binding model. Three structures, shCD38 (dark green), CD157 (yellow),
and Aplysia cyclase (pink), are aligned based on their conserved active site residues. Substrate cADPR is also drawn with the color scheme:
C, gray; N, blue; O, pink; P, red. The Etheno-NADP (yellow) in CD157 is shown for comparison. The dashed lines represent the polar interac-
tions between the enzymes and substrates/substrate analogs.
(C) The model of cADPR in the active site of shCD38. Functionally essential residues are marked on the electrostatic surface. Negative
potential is colored in red, and positive potential is colored in blue.
(D) Stereoview of the CD38-NMN binding model. The color scheme is the same as in (B). NMN is a substrate of CD38.
(E) The schematic diagram of the role of Glu146 during the synthesis of cADPR from NAD.that the binding of cADPR requires both the hydropho-
bic sites (Trp125 and Trp189) and the hydrophilic site
(Lys129).
The distance between the Lys129 Nζ atom and ribose
(on the indole ring side) is 3.2 Å, thus permitting CD38
to bind to cADPR. This residue is not conserved in the
ADP-ribosyl cyclase family. The corresponding resi-
dues in CD157 and Aplysia cyclase are His81 and Tyr81,
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despectively. It is interesting that, in the CD157 Etheno-
ADP binding model, His81 also has the hydrogen
ond interaction to Etheno-NADP (Figure 5B), whereas
n Aplysia cyclase, the OH moiety of Tyr81 points away
rom the cADPR, which does not favor a similar polar
nteraction. Such structural information, together with
he fact that Aplysia cyclase does not have cADPR hy-
rolysis activity, suggests that the hydrogen bond plays
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Residue Lys129 is located at the entrance of the cata-
lytic pocket. It is possible that the breaking of this hy-
drogen bond will disable the binding and the entry of
cADPR into the catalytic pocket and prevent the hydro-
lysis reaction from occurring.
Cyclase Activity and NADase Activity Is Regulated
by Residue146
The synthesis of cADPR requires two steps: the cleav-
age of the nicotinamide-ribose bond from NAD, fol-
lowed by the entry of the adenine moiety and cycliza-
tion (Yamamoto-Katayama et al., 2002). Residue Glu146,
conserved in Aplysia cyclase, but not in CD157, has
been shown to have an important role in regulating the
ratio of CD38’s cyclase and NADase activities (Graeff
et al., 2001). Wild-type CD38 has high NADase activ-
ity, but only minimal cyclase activity. Interestingly, the
E146A mutant of CD38, however, has greatly increased
cyclase activity and decreased NADase activity (Graeff
et al., 2001). NMN is a mimic substrate of NAD and can
be hydrolyzed by CD38 (Sauve et al., 2000).
In the CD38-NMN model, Glu146 forms hydrogen
bond interactions with NMN (Figure 5D), revealing its
role in the catalysis. The polar interaction between
Glu146 and the nicotinamide moiety of NMN is likely
to interfere with the release of nicotinamide. The slow
release of nicotinamide prevents the entry of the ade-
nine moiety to the active site for the cyclization reac-
tion; thus, the hydrolysis reaction dominates at the
active site in the wild-type CD38. In the E146A mutant,
such hydrogen bond interactions do not exist, favoring
a fast release of nicotinamide and the entry of the ade-
nine moiety of NAD for the ADP-ribosyl cyclase activity.
In the CD38-Etheno-NADP model, Glu146 has a polar
interaction to the N atom on the adenine ring with a
distance of 2.8 Å (Figure 5B). This hydrogen bond
shows the function of Glu146 in folding back the ade-
nine ring for the subsequent cyclization reaction after
the cleavage of nicotinamide. That is, Glu146 can facili-
tate the recruitment of the adenine moiety and stabilize
the adenine through the hydrogen bonding interaction.
As shown in Figure 5B, the cyclization reaction needs
aw60° rotation of the adenine ring around the adenine-
glycosidic bond to form cyclic ADPR. Accordingly, the
rotation of the adenine moiety enables its N atom to be
closer to the reaction intermediate formed by substrate
and the enzyme. The intermediate is not stable; there-
fore, the approaching N atom can then act as a nucleo-
phile to attack the reaction intermediate and produce
cADPR. At the same time, the breaking of the sub-
strate-enzyme intermediate may facilitate the move-
ment of the glycosidic moiety to the adenine moiety,
thus benefiting the cyclization process (Figure 5B). The
role of residue Glu146 in the synthesis of cADPR is
summarized in a schematic drawing (Figure 5E).
Experimental Procedures
Protein Expression, Purification, and Crystallization
The soluble human CD38 was expressed in the yeast Pichia pas-
toris strain X-33 with the expression vector pPICZαA (Invitrogen,
Carlsbad, CA) under the control of an alcohol oxidase promoter
and the secretion sequence of the α-mating factor as previouslyTable 1. Crystallographic Data and Refinement Statistics
Data Collection
Cell dimensions (Å)/(°) a = 41.84, b = 51.50, c = 66.44/
α = 108.27, β = 90.47, γ = 97.29
Space group P1
Resolution (Å)a 30–1.90 (1.93–1.90)
Unique reflections 40,203
Multiplicity 3.8
I/σ 13.7 (3.1)
Rsym (%) 7.7 (42.6)
Completeness (%) 97.9 (94.6)
Refinement
R factor (%) 18.85
Rfree factor (%) 25.34
Rms deviations
Bond lengths (Å) 0.03
Bond angles (°) 2.26
a Values in parentheses are from the highest-resolution shell.described (Munshi et al., 2000). The N-terminal intracellular domain
and transmembrane domain were deleted to obviate the trafficking
of the secreted proteins to the plasma membrane. Four proposed
glycosylation sites were silenced by site-directed mutagenesis
(N100D, N164A, N209D, and N219D) to prevent the posttransla-
tional modifications.
Yeast containing the expression vector for CD38 was grown in a
fermentation reactor and induced to express and secrete CD38 by
methanol as described previously (Munshi et al., 1997). At the end
of the fermentation period, the yeast cells and debris were removed
by centrifugation at 5000 × g for 15 min, and the supernatant was
stored at −80°C until purification. CD38 was purified from the fer-
mentation medium in two steps. The supernatant was supple-
mented with 1 M KCl, filtered, and applied to a Phenylsepharose
CL-4B column (2.5 cm × 10 cm) at a flow rate of 2.5 ml/min. Vol-
umes of 100 ml were processed at one time. Following application
of the sample, the column was rinsed with 100 ml of a solution
containing 20 mM HEPES (pH 7.5), 2 M KCl. Most of the color and
salts from the fermentation medium did not adhere to the column.
The retained CD38 protein was eluted with a solution of 20 mM
HEPES (pH 7.5). Fractions of 5 ml were collected, and the activity
of CD38 was monitored fluorometrically by the conversion of the
nonfluorescent NGD substrate to the fluorescent cyclic GDP-ribose
product (Graeff et al., 1996). Active fractions were pooled and dia-
lyzed overnight against 50 mM sodium acetate (pH 4) (buffer A).
The recovered protein was filtered and injected onto an 8 × 75 mm
Waters SP 5PW cation exchange column at a flow rate of 0.5 ml/
min. Injection volumes of 5 ml were repeated until the 100 ml sam-
ple was applied. CD38 was eluted with a linear gradient of 50 mM
sodium acetate (pH 4), 1 M NaCl (buffer B). The fractions near the
peak of the CD38 protein were adjusted to pH 7 with Tris base and
were assayed for activity by using NGD as a substrate as described
above. The peak fractions were pooled and dialyzed overnight
against a buffer containing 25 mM HEPES (pH 7), 50 mM NaCl.
Besides activity, the purity of the CD38 was checked by SDS poly-
acryamide gel electrophoresis; CD38 ran as a single band with a
MW of approximately 30 kDa. The purified CD38 was adjusted to
a protein concentration of 8 mg/ml with centricon concentrators
(Millipore, 10,000 MWCO).
Usable crystals were obtained by using the hanging drop vapor
diffusion technique with 1 l protein solution equilibrated with 1 l
precipitant solution containing 100 mM Na MES (pH 6.5) and 26%
PEG 4000.
Data Collection, Reduction, and Structure Determination
X-ray diffraction data were collected to a resolution limit of 1.9 Å
from a single frozen crystal at the Cornell High-Energy Synchrotron
Source (CHESS) F1 station under cryoprotection at 100 K at a fixed
wavelength of 0.916 Å. A total of 360 images with an oscillation
angle of 1° were collected by using a Quantum-4 CCD detector.
The complete data set was reduced by using the program package
Structure
1338DENZO/SCALEPACK (Otwinowski and Minor, 1997). The crystallo-
graphic statistics are listed in Table 1.
There are two shCD38 molecules in the asymmetric unit of the
crystal in space group P1 andw30% sequence identities between
shCD38 and its closest homolog, BST-1. The initial molecular re-
placement using either subunit A or subunit B of BST-1 (PDB ID:
1ISF) as a search model failed to give a reasonable solution. Then,
the model was modified: (1) all side chains of loop region residues
were truncated; (2) the B factors for all atoms were fixed to 40 Å2;
(3) all side chains in the search model that are different from
shCD38 were deleted based on the sequence alignment between
shCD38 and BST-1. After the modification, a number of possible
solutions were obtained by using the program AMoRe (Navaza,
1994). From the output, the rotational peak for the first is obvious.
However, there is no clear rotational peak for the second molecule.
A pair of solutions (1st and 4th on the original AMoRe peak list) was
chosen because they were related by the same 2-fold axis as was
calculated by using the program ALMN (CCP4, 1994). After 20 cy-
cles of rigid body refinement, the model phases were calculated
and were subjected to 100 cycles of density modifications with
2-fold NCS averaging as implemented in the program DM (CCP4,
1994) at 1.90 Å resolution. The full shCD38 model could then man-
ually be built in O (Jones et al., 1991) based on the electron density
calculated from the DM phases and experimental amplitudes. The
subsequent structural refinement was done with the program
REFMAC (CCP4, 1994), and the final model was refined to con-
verge with an R factor and an Rfree of 18.85% and 25.34%, respec-
tively.
Modeling cADPR and NMN into the Catalytic Sites
To model cADPR and NMN into shCD38, the complex structures of
CD157 with its substrate analog Etheno-NADP and substrate NMN
(PDB ID: 1ISH and 1ISJ, respectively) were aligned to CD38 based
on a least square optimization for all atoms in three conserved resi-
dues (Glu226, Trp125, and Trp189) within the active site. The sub-
strate cADPR, using its crystal coordinates (Lee et al., 1994; Lee,
2002), was then manually fitted into CD38 with a best match to
Etheno-NADP. No atomic clashes were found in the CD38-cADPR
model. The conjugate gradient energy minimization method imple-
mented in CNS (Brunger et al., 1998) was used to fit the positions
of cADPR and NMN for studying the interactions between CD38
and cADPR.
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